Vnitr Lek 2016, 62(Suppl 3):92-98

Thyroid hormones and cardiovascular system

Zdeňka Límanová*, Jan Jiskra
III. interní klinika 1. LF UK a VFN v Praze

Cardiovascular system is essentially affected by thyroid hormones by way of their genomic and non-genomic effects. Untreated overt thyroid dysfunction is associated with higher cardiovascular risk. Although it has been studied more than 3 decades, in subclinical thyroid dysfunction the negative effect on cardiovascular system is much more controversial. Large meta-analyses within last 10 years have shown that subclinical hyperthyroidism is associated with higher cardiovascular risk than subclinical hypothyroidism. Conversely, in patients of age > 85 years subclinical hypothyroidism was linked with lower mortality. Therefore, subclinical hyperthyroidism should be rather treated in the elderly while subclinical hypothyroidism in the younger patients and the older may be just followed. An important problem on the border of endocrinology and cardiology is amiodarone thyroid dysfunction. Effective and safe treatment is preconditioned by distinguishing of type 1 and type 2 amiodarone induced hyperthyroidism. The type 1 should be treated with methimazol, therapeutic response is prolonged, according to recent knowledge immediate discontinuation of amiodarone is not routinely recommended and patient should be usually prepared to total thyroidectomy, or rather rarely 131I radioiodine ablation may be used if there is appropriate accumulation. In the type 2 there is a promt therapeutic response on glucocorticoids (within 1-2 weeks) with permanent remission or development of hypothyroidism. If it is not used for life-threatening arrhytmias, amiodarone may be discontinuated earlier (after several weeks). Amiodarone induced hypothyroidism is treated with levothyroxine without amiodarone interruption.

Keywords: amiodarone induced thyroid dysfunction; atrial fibrillation; cardiovascular risk; heart failure; hyperthyroidism; hypothyroidism; thyroid stimulating hormone

Received: August 10, 2016; Accepted: September 6, 2016; Published: June 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Límanová Z, Jiskra J. Thyroid hormones and cardiovascular system. Vnitr Lek. 2016;62(Supplementum 3):92-98.
Download citation

References

  1. Thomayer J. Pathologie a therapie nemocí vnitřních. 4. ed. Bursík J, Kohout F, Praha 1921: 487-507.
  2. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation 2010; 122(4): 385-393. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA>. Go to original source... Go to PubMed...
  3. Galli E, Pingitore A, Iervasi G. The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence. Heart Fail Rev 2010; 15(2): 155-169. Dostupné z DOI: <http://dx.doi.org/.1007/s10741-008-9126-6>. Go to original source... Go to PubMed...
  4. Biondi B. Heart failure and thyroid dysfunction. Eur J Endocrinol 2012; 167(5): 609-618. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-12-0627>. Go to original source... Go to PubMed...
  5. Friesema EC, Ganguly S, Abdalla A et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003; 278(41): 40128-40135. Go to original source... Go to PubMed...
  6. Flamant F, Baxter JD, Forrest D et al. International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol Rev 2006; 58(4): 705-711. Go to original source... Go to PubMed...
  7. Kliewer SA, Umesono K, Mangelsdorf DJ et al. Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992; 355(6359): 446-449. Go to original source... Go to PubMed...
  8. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat Rev Endocrinol 2016; 12(2): 111-121. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2015.205>. Go to original source... Go to PubMed...
  9. Vassy R, Nicolas P, Yin YL et al. Nongenomic effect of triiodothyronine on cell surface beta-adrenoceptors in cultured embryonic cardiac myocytes. Proc Soc Exp Biol Med 1997; 214(4): 352-358. Go to original source... Go to PubMed...
  10. Abdalla SM, Bianco AC. Defending plasma T3 is a biological priority. Endocrinol (Oxf) 2014; 81(5): 633-641. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12538>. Go to original source... Go to PubMed...
  11. Vanden Berge G. Non-thyroidal illness in the ICU: a syndrome with different faces. Thyroid 2014; 24(10): 1456-1465. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2014.0201>. Go to original source... Go to PubMed...
  12. Fraczek MM, Łacka K. Thyroid hormone and the cardiovascular system. Pol Merkur Lekarski 2014; 37(219): 170-174. Go to PubMed...
  13. Límanová Z, Šimonová J. Změny tyreoidáních hormonů u čerstvého srdečního infarktu. Vnitř Lék 1984; 30(12): 1177-1185. Go to PubMed...
  14. Mayer O Jr, Simon J, Filipovský J et al. Hypothyroidism in coronary heart disease and its relation to selected risk factors. Vasc Health Risk Manag 2006; 2(4): 499-506. Go to original source... Go to PubMed...
  15. Lee JJ, Pedley A, Marqusee E et al. Thyroid Function and Cardiovascular Disease Risk Factors in Euthyroid Adults: A Cross-Sectional and Longitudinal Study. Clin Endocrinol (Oxf) 2016. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.13124>. Go to original source... Go to PubMed...
  16. Levarsie G, Molinaro S, Landi P et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 2007; 167(14): 1526-1532. Go to original source... Go to PubMed...
  17. Singer RB. Mortality in a complete 4-year follow up of 85-year-old residents of Leiden, classified by serum level of thyrotropin and thyroxine. J Insur Med 2006; 38(1): 14-19. Go to PubMed...
  18. Ochs N, Auer R, Bauer DC et al. Metaanalysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148(11): 832-845. Go to original source... Go to PubMed...
  19. Mariotti S. Mild hypothyroidism and ischemic heart disease: Is age the answer? J Clin Endocrinol Metab 2008; 93(8): 2969-2971. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2008-1237>. Go to original source... Go to PubMed...
  20. Hyland KA, Arnold AM, Lee JS et al. Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study. J Clin Endocrinol Metab 2013; 98(2): 533-540. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012-2180>. Go to original source... Go to PubMed...
  21. Selmer C, Olesen JB, Hansen ML et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014; 99(7): 2372-2382. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013-4184>. Go to original source... Go to PubMed...
  22. Grossman A, Weiss A, Koren-Morag N et al. Subclinical thyroid disease and mortality in the elderly: a retrospective cohort study. Am J Med 2016; 129(4): 423-430. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2015.11.027>. Go to original source... Go to PubMed...
  23. Olivieri O, Girelli D, Azzizi M et al. Low selenium status in elderly influences thyroid hormones. Clin-Sci 1995; 89(6): 637-642. Go to original source... Go to PubMed...
  24. Markovič NS, Djurica S, Brajovič M et al. Dilated cardiomyopathy with autoimmune disease of thyroid gland. Srp Arth Celok Lek 2005; 133(Suppl 1): 46-51. Go to original source... Go to PubMed...
  25. Sawin CT, Geller A, Wolf P et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrilation in older persons. N Engl J Med 1994; 331(19): 1249-1952. Go to original source... Go to PubMed...
  26. Maity S, Kar D, De k et al. Hyperthyroidism causes cardiac dysfunction by mitochondrial impairment end energy depletion. J Endocrinol 2013; 217(2):215-228. Dostupné z DOI: <http://dx.doi.org/10.1530/JOE-12-0304>. Go to original source... Go to PubMed...
  27. Tamer I, Sargin M, Sargin H et al. The evaluation of left ventricular hypertrophy in hypertensive patients with subclinical hyperthyroidism. Endocr J 2005; 52(4): 421-425. Go to original source... Go to PubMed...
  28. Rodondi N, Bauer DC, Cappola AR et al. Subclinical thyroid disease linked with modest risk of heart disease and mortality. J Am Coll Cardiol 2008; 52(14): 1152-1159. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.07.009>. Go to original source... Go to PubMed...
  29. Cappola AR, Fried L, Arnold A et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295(9): 1033-1041. Go to original source... Go to PubMed...
  30. Völzke H, Schwahn C, Wallaschofski H et al. Review: The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? J Clin Endocrinol Metab 2007; 92(7): 2421-2429. Go to original source... Go to PubMed...
  31. Singh S, Duggal J, Molnar J et al. Impact of subclinical hyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 2008; 125(1): 41-48. Go to original source... Go to PubMed...
  32. Collet TH, Gussekloo J, Bauer DC et al. Thyroid Studies Collaboration: Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172(10): 799-809. Dostupné z DOI: <http://dx.doi.org/10.1001/archinternmed.2012.402>. Go to original source... Go to PubMed...
  33. Haentjens P, Van Meerhaeghe A, Poppe K et al. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008; 159(3): 329-341. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-08-0110>. Go to original source... Go to PubMed...
  34. Yang LB, Jiang DQ, Qi WB et al. Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. Eur J Endocrinol 2012; 167(1): 75-84. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-12-0015>. Go to original source... Go to PubMed...
  35. Sapp JL, Wells GA, Parkash R et al. Ventricular tachycardiac ablation versus escalation of antiarrhytmic drugs. New Engl J Med 2016; 375(2): 111-121. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1513614>. Go to original source... Go to PubMed...
  36. Batcher EL, Tang XC, Singh BN et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med 2007; 120(10): 880. Go to original source... Go to PubMed...
  37. van Beeren HC, Bakker O, Wiersinga WM. Structure-function relationship of the inhibition of the 3,5,3'-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs. Endocrinology 1996; 137(7): 2807-2814. Go to original source... Go to PubMed...
  38. Ross DS. Amiodarone and thyroid dysfunction. Up to Date. Section editor Cooper DS. Dostupné z WWW: <http://www.uptodate.com/contents/amiodarone-and-thyroid-dysfunction >.
  39. Maqdasy S, Batisse-Lignier M, Auclair C et al. Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. Am J Cardiol 2016; 117(7): 1112-1116. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2016.01.003>. Go to original source... Go to PubMed...
  40. Uzan L, Guignat L, Meune C et al. Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. Drug Saf 2006; 29(3): 231. Go to original source... Go to PubMed...
  41. Eskes SA, Endert E, Fliers E et al. Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. J Clin Endocrinol Metab 2012; 97(2): 499-506. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011-2390>. Go to original source... Go to PubMed...
  42. Kurnik D, Loebstein R, Farfel Z et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004; 83(2): 107. Go to original source... Go to PubMed...
  43. Doggrell SA, Hancox JC. Dronedarone: an amiodarone analogue. Expert Opin Investig Drugs 2004; 13(4): 415-426. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.